Backlash Over $106B Pfizer-AstraZeneca Deal Spans Atlantic
A U.S. senator and two governors on Thursday sharply criticized the prospective $106 billion merger between drug giants Pfizer Inc. and AstraZeneca PLC, piling tax concerns and job cut worries onto...To view the full article, register now.
Already a subscriber? Click here to view full article